Drug Interactions between cefpodoxime and Myrbetriq
This report displays the potential drug interactions for the following 2 drugs:
- cefpodoxime
- Myrbetriq (mirabegron)
Interactions between your drugs
No interactions were found between cefpodoxime and Myrbetriq. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
cefpodoxime
A total of 84 drugs are known to interact with cefpodoxime.
- Cefpodoxime is in the drug class third generation cephalosporins.
- Cefpodoxime is used to treat the following conditions:
Myrbetriq
A total of 250 drugs are known to interact with Myrbetriq.
- Myrbetriq is in the drug class urinary antispasmodics.
- Myrbetriq is used to treat the following conditions:
Drug and food interactions
cefpodoxime food
Applies to: cefpodoxime
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of cefpodoxime proxetil tablets. Following a 200 mg dose taken with food, the extent of absorption (mean AUC) was 21% to 33% higher and the mean peak plasma concentration (Cmax) 19% higher than under fasting conditions. Time to peak concentration (Tmax) was not significantly different between fed and fasted states. On the contrary, when a 200 mg dose of the suspension was taken with food, the mean AUC and Cmax were not significantly different than those under fasting conditions, although the rate of absorption was slower with food (48% increase in Tmax ).
MANAGEMENT: To ensure maximal oral absorption, cefpodoxime proxetil tablets should be administered with or immediately after a meal.
References (3)
- Hughes GS, Heald DL, Barker KB, et al. (1989) "The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil." Clin Pharmacol Ther, 46, p. 674-85
- "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn
- Borin MT, Driver MR, Forbes KK (1995) "Effect of timing of food on absorption of cefpodoxime proxetil." J Clin Pharmacol, 35, p. 505-9
mirabegron food
Applies to: Myrbetriq (mirabegron)
Food reduces the oral absorption and bioavailability of mirabegron. According to the product labeling, administration of a 50 mg tablet with a high-fat meal decreased mirabegron peak plasma concentration (Cmax) and systemic exposure (AUC) by 45% and 17%, respectively, whereas administration with a low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively. In phase 3 clinical studies demonstrating both safety and efficacy, mirabegron was administered without regards to food content and intake. Therefore, mirabegron can be taken with or without food at the recommended dosage.
References (1)
- (2012) "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.